Navigate to
-
Jan. 28, 2025 – hydrochlorothiazide (Inzirqo) 505(b)(2) NDA approval; Standard Review; first oral suspension formulation of hydrochlorothiazide; previously available oral solutions are no longer...
-
Abbvie is seeking Accelerated Approval of Teliso-V in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell...
-
January 31, 2025 All brand names are property of their respective owners. Dec. 13, 2024 – cosibelimab-ipdl (Unloxcyt) Checkpoint’s Unloxcyt has received FDA approval for the treatment of adults...
-
Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Non-Diabetic Obese Commercially Insured Adults Authors: A.M. Wilson, PharmD; B.D. Hunter, MS; K....